You can buy or sell ACRX and other stocks, options, ETFs, and crypto commission-free!
AcelRx Pharmaceuticals, Inc. engages in the development and commercialization of therapies use in medically supervised settings. Its products include sufentanil, DZUVEO, DSUVIA ZALVISO US and ZALVISO EU. Read More The company was founded by Thomas A. Schreck and Pamela Pierce Palmer on July 13, 2005 and is headquartered in Redwood City, CA.
Redwood City, California
52 Week High
52 Week Low
Yahoo FinanceMay 9
Edited Transcript of ACRX earnings conference call or presentation 8-May-19 8:30pm GMT
Q1 2019 AcelRx Pharmaceuticals Inc Earnings Call REDWOOD CITY May 9, 2019 (Thomson StreetEvents) -- Edited Transcript of AcelRx Pharmaceuticals Inc earnings conference call or presentation Wednesday, May 8, 2019 at 8:30:00pm GMT TEXT version of Transcript ================================================================================ Corporate Participants ================================================================================ * Pamela Pierce Palmer AcelRx Pharmaceuticals, Inc. - Co-Founder...
Yahoo FinanceMay 8
AcelRx Pharmaceuticals Reports Q1 Loss, Lags Revenue Estimates
AcelRx Pharmaceuticals (ACRX) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to loss of $0.23 per share a year ago.
PR NewswireMay 8
AcelRx Pharmaceuticals Reports First Quarter 2019 Financial Results
REDWOOD CITY, Calif., May 8, 2019 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today reported its first quarter 2019 financial results. "I am very pleased with the progress made in the first five weeks of the DSUVIA™ launch. Shifting the paradigm in healthcare facilities to a new, non-invasive treatment option for acute pain will tak...
-$0.22 per share
-$0.17 per share